

Selpercatinib LIBRETTO-531

### PRELIMINARY SCORE

#### CURATIVE



#### NON-CURATIVE



### ADJUSTMENTS

#### Quality of life



QoL data pending



#### Serious and disabling adverse effects



#### Other adjustments



Long-term plateau in the PFS curve



Selpercatinib LIBRETTO-531

### SCORE

#### CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

#### NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

#### INFORMATION

Tumour type: Endocrine Tumours  
 Therapeutic Indication: Selpercatinib for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.  
 Experimental Arm: Selpercatinib  
 Control Arm: Cabozantinib or Vandetanib



